rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Kairos Pharma, Ltd.

KAPA · NYSE American

Health CareBiotechnologyNot moving yet

KAPA stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 78.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
13 (+3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$9,474Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13+3 on the quarter
New · exited6 · 3
Reported value$340K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 2026309,834$119K+309,834
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026231,878$89K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202678,924$30K-32,366−29.1%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202663,884$25K00.0%
Aptus Capital Advisors, LLCunchanged · filed 12 Aug 202644,286$17K00.0%
SevenBridge Financial Group, LLCunchanged · filed 12 Aug 202644,286$17K00.0%
JANE STREET GROUP, LLCnew · filed 14 Aug 202633,749$13K+33,749
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202629,292$11K+29,292
STATE STREET CORPunchanged · filed 7 Aug 202624,100$9,24700.0%
XTX Topco Ltdnew · filed 14 Aug 202614,918$5,724+14,918
30 Sep 2024 – 30 Jun 2026
2813Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Doug Samuelson Company insiderChief Financial Officer · last 8 Oct 20251 · 0
Hansoo Michael Keyoung Company insiderDirector · last 8 Oct 20250 · 0
Hyun W. Bae Company insiderDirector · last 8 Oct 20250 · 0
John S. Yu Company insiderCEO and Chairman · last 8 Oct 20251 · 0
Neil Bhowmick Company insiderChief Scientific Officer · last 8 Oct 20250 · 0
Rahul Singhvi Company insiderDirector · last 8 Oct 20250 · 0
Ramachandran Murali Company insiderVP of Research and Development · last 8 Oct 20251 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-87.9%
Share count trendFY 2025 · to 31 Mar 20262.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.5M

Analyst forecasts

No analyst forecasts yet.